# Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

> **NCT03325166** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 2 (actual)

## Conditions studied

- Lung Carcinoma Metastatic in the Brain
- Stage IV Lung Non-Small Cell Cancer AJCC v7

## Interventions

- **DRUG:** Ferumoxytol
- **OTHER:** Laboratory Biomarker Analysis
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03325166
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-11-03
- **Primary completion:** 2021-03-01
- **Final completion:** 2021-03-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2022-08-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03325166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03325166, "Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03325166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*